Navigation Links
Dendreon Announces Change in Board of Directors
Date:9/14/2010

SEATTLE, Sept. 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark, chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group, has resigned from the company's Board of Directors.

"It's been rewarding to serve on the board at one of the most exciting periods in Dendreon's history," said Mr. Clark. "Unfortunately, my job responsibilities currently limit the time I can devote to be an effective director to Dendreon at this time, and I wish the management team and employees continued success as they realize their mission of transforming the lives of patients with cancer." 

"We appreciate Ian's contributions during this pivotal time and wish him the best in his endeavors at Genentech," said Richard B. Brewer, chairman of the Dendreon Board of Directors.

About Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first autologous cellular immunotherapy product, PROVENGE(R) (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  A novel biomarker ... help physicians better identify early-stage disease, when treatment ... according to a new study in The Journal ... (NYSE: DGX ) and other institutions ... protein outperformed conventional antibody-serum testing, including rheumatoid factor ...
(Date:8/27/2014)... Westminster, CO (PRWEB) August 27, 2014 ... image analysis services to the pharmaceutical and medical ... and expansion. The fast growing company has consolidated ... in Aurora and Boulder to Westminster, CO, just north ... and Histology Lab, 7575 W. 103rd Ave., Suite 100, ...
(Date:8/27/2014)... JUNCTION, N.J. , Aug. 27, 2014 ... innovative drug delivery technologies, today announced that it has ... Jersey Business & Industry Association,s 2014 Awards for ... were selected by an independent panel of judges from ... company volunteers. Award winners will be honored at a ...
(Date:8/27/2014)... According to the 2013 Raw Material and ... and feel of markets for raw materials and ingredient ... push for more branded, science-backed products.” , Natural products ... growth in the last decade as consumers increasingly demand ... to fit a more ‘wellness’ lifestyle approach. Due ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Flagship Biosciences Announces Relocation and Expansion 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... Md., Oct. 24 MedImmune, Inc. announced,today that ... recognized the company for its employees, exceptional commitment ... Volunteer Award,for a large business. "As the ... as an outstanding corporate citizen whose employees strive ...
... Oct. 24 Gene Codes Corporation, a,leading ... the next version of Sequencher, its award-winning,Deoxyribonucleic ... Researchers in academic labs and pharmaceutical ... the essential genetic instructions key to,an organism,s ...
... - Atrium Innovations Inc. (TSX:,ATB) will hold its ... Eastern,time on November 8, 2007. The call will ... results issued earlier the previous day.,Participants may access ... or 800-591-7539 or via the Company,s website at, ...
Cached Biology Technology:Gene Codes Corporation Announces Version 4.8 of Sequencher Software for DNA Sequence Assembly & Analysis 2Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8 2
(Date:8/27/2014)... pathogens posing the greatest risk to Europe based upon ... of Liverpool researchers using a ,big data, approach to ... of Infection and Global Health ranked the top 100 ... animals using a system which, they believe, will help ... the spread of infectious diseases, including as a result ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... Outstanding basic research, a growing focus on translating ... care have earned the Herbert Irving Comprehensive Cancer ... and NewYork-Presbyterian Hospital an $18 million, five-year Cancer ... (NCI). The grant renews the center,s status as ... in New York City and one of only ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... -- Two research groups from the University of Tennessee, ... Science Foundation to create new graduate research and education ... grants, called Integrative Graduate Education and Research Traineeships, or ... students to UT Knoxville for two unique programs that ...
... . , Since Monday of this week, the ... in Neuss, Germany, where it is being tested for safety ... has been in use since 1921, and has been genetically ... than its predecessor. The scientific basis for this was ...
... Philadelphia, PA, September 11, 2008 People who are ... and a "bad" snack might not follow their intentions ... September/October 2008 issue of the Journal of Nutrition ... is a substantial inconsistency between healthful snack choice intentions ...
Cached Biology News:UT Knoxville wins 2 $3M National Science Foundation research and education grants 2Clinical trial for new tuberculosis vaccine 2Making snack food choices 2
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
... Dyad thermal cycler is a flexible ... chassis accommodates a variety of interchangeable ... hold different types and numbers of ... with point-and-click navigation. Peltier heat pumps, ...
... Immunophosphatase Secondary Detection System is intended for ... Primary Antibody reagents, which contain rat and ... antigens by light microscopy in paraffin-embedded tissues. ... may also be used with other rat ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
Biology Products: